Journal Home > Volume 1 , Issue 1
Background:

Many previous studies have focused on the effects of IN-1, a monoclonal antibody that neutralizes Nogo (a neurite growth inhibitory protein), on neurologic regeneration in spinal cord injury (SCI). However, safety problems and the short half-life of the exogenous antibody are still problematic. In the present study, the NogoA polypeptide was used as an antigen to make a therapeutic NogoA vaccine. Rats were immunized with this vaccine and were able to secrete the polyclonal antibody before SCI. The antibody can block NogoA within the injured spinal cord when the antibody gains access to the spinal cord due to a compromised blood–spinal cord barrier. Olfactory ensheathing glial cell transplantation has been used in a spinal cord contusion model to promote the recovery of SCI. The present study was designed to verify the efficacy and safety of NogoA polypeptide vaccine, the effects of immunotherapy with this vaccine, and the synergistic effects of the vaccine and olfactory ensheathing glial cells in repair of SCI.

Methods:

A 13-polypeptide fragment of NogoA was synthesized. This fragment was then coupled with keyhole limpet hemocyanin to improve the immunogenicity of the polypeptide vaccine. Immunization via injection into the abdominal cavity was performed in rats before SCI. The serum antibody level and ability of the vaccine to bind with Nogo were detected by enzyme-linked immunosorbent assay. The safety of the vaccine was evaluated according to the incidence and severity of experimental autoimmune encephalomyelitis. Olfactory ensheathing glia cells were obtained, purified, and subsequently implanted into a Wistar rat model of thoracic spinal cord contusion injury. The rats were divided into four groups, ie, an SCI model group, an olfactory ensheathing glia group, a vaccine group, and a combined treatment group. Animal behavior, histopathology, and axonal regeneration were compared between the four treatment groups.

Results:

The antibody against the polypeptide was detected in rat serum by enzyme-linked immunosorbent assay. Experimental autoimmune encephalomyelitis was not found in the immunized rats. Three months after injury, Basso, Beattie, Bresnahan scores and nerve fiber counts in biotinylated dextran amine nerve tracing studies were significantly better in the combined treatment group than in the other groups.

Conclusion:

The polypeptide NogoA vaccine can stimulate the humoral immune system to produce antibodies against the NogoA polypeptide. The binding reaction between the antibody and antigen was shown in ex vivo experiments. No evidence was found to suggest a relationship between NogoA vaccination and increased risk of experimental autoimmune encephalomyelitis. The combined strategy of olfactory ensheathing glial cell implantation and NogoA vaccination may promote regeneration of axons and functional recovery in the spinal cord contusion injury model. This study may provide a new strategy for combining modalities to enhance axonal regeneration and a better balance of the CNS microenvironment after SCI.


menu
Abstract
Full text
Outline
About this article

Therapeutic effects of NogoA vaccine and olfactory ensheathing glial cell implantation on acute spinal cord injury

Show Author's information Zhicheng ZhangFang LiTiansheng Sun( )Dajiang RenXiumei Liu
PLA Institute of Orthopedics, Beijing Army General Hospital, Beijing, People’s Republic of China

Abstract

Background:

Many previous studies have focused on the effects of IN-1, a monoclonal antibody that neutralizes Nogo (a neurite growth inhibitory protein), on neurologic regeneration in spinal cord injury (SCI). However, safety problems and the short half-life of the exogenous antibody are still problematic. In the present study, the NogoA polypeptide was used as an antigen to make a therapeutic NogoA vaccine. Rats were immunized with this vaccine and were able to secrete the polyclonal antibody before SCI. The antibody can block NogoA within the injured spinal cord when the antibody gains access to the spinal cord due to a compromised blood–spinal cord barrier. Olfactory ensheathing glial cell transplantation has been used in a spinal cord contusion model to promote the recovery of SCI. The present study was designed to verify the efficacy and safety of NogoA polypeptide vaccine, the effects of immunotherapy with this vaccine, and the synergistic effects of the vaccine and olfactory ensheathing glial cells in repair of SCI.

Methods:

A 13-polypeptide fragment of NogoA was synthesized. This fragment was then coupled with keyhole limpet hemocyanin to improve the immunogenicity of the polypeptide vaccine. Immunization via injection into the abdominal cavity was performed in rats before SCI. The serum antibody level and ability of the vaccine to bind with Nogo were detected by enzyme-linked immunosorbent assay. The safety of the vaccine was evaluated according to the incidence and severity of experimental autoimmune encephalomyelitis. Olfactory ensheathing glia cells were obtained, purified, and subsequently implanted into a Wistar rat model of thoracic spinal cord contusion injury. The rats were divided into four groups, ie, an SCI model group, an olfactory ensheathing glia group, a vaccine group, and a combined treatment group. Animal behavior, histopathology, and axonal regeneration were compared between the four treatment groups.

Results:

The antibody against the polypeptide was detected in rat serum by enzyme-linked immunosorbent assay. Experimental autoimmune encephalomyelitis was not found in the immunized rats. Three months after injury, Basso, Beattie, Bresnahan scores and nerve fiber counts in biotinylated dextran amine nerve tracing studies were significantly better in the combined treatment group than in the other groups.

Conclusion:

The polypeptide NogoA vaccine can stimulate the humoral immune system to produce antibodies against the NogoA polypeptide. The binding reaction between the antibody and antigen was shown in ex vivo experiments. No evidence was found to suggest a relationship between NogoA vaccination and increased risk of experimental autoimmune encephalomyelitis. The combined strategy of olfactory ensheathing glial cell implantation and NogoA vaccination may promote regeneration of axons and functional recovery in the spinal cord contusion injury model. This study may provide a new strategy for combining modalities to enhance axonal regeneration and a better balance of the CNS microenvironment after SCI.

Keywords: immunotherapy, cell transplantation, spinal cord injury, vaccine, olfactory ensheathing glial cells, NogoA

References(24)

1.
Benfey M, Aguayo AJ. Extensive elongation of axons from rat brain into peripheral nerve grafts. Nature. 1982;296:150–152.
2.
Horner PL, Gage FH. Regenerating the damaged central nervous system. Nature. 2000;407:963–970.
3.
Hernández J, Torres-Espín A, Navarro X. Adult stem cell transplants for spinal cord injury repair: current state in preclinical research. Curr Stem Cell Res Ther. 2011;6:273–287.
4.
Blesch A, Fischer I, Tuszynski MH. Gene therapy, neurotrophic factors and spinal cord regeneration. Handb Clin Neurol. 2012;109: 563–574.
5.
Raisman G, Barnett SC, Ramón-Cueto A. Repair of central nervous system lesions by transplantation of olfactory ensheathing cells. Handb Clin Neurol. 2012;109:541–549.
6.
Wu J, Sun TS, Ren JX, et al. Ex vivo non-viral vector-mediated neurotrophin-3 gene transfer to olfactory ensheathing glia: effects on axonal regeneration and functional recovery after implantation in rats with spinal cord injury. Neurosci Bull. 2008;24:57–65.
7.
Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12:1–21.
8.
Huber AB, Schwab ME. Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol Chem. 2000;381:407–419.
9.
Xie F, Zheng B. White matter inhibitors in CNS axon regeneration failure. Exp Neurol. 2008;209:302–312.
10.
Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol. 2008;209: 294–301.
11.
Bourquin C, van der Haar ME, Anz D, et al. DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis. Eur J Pharmacol. 2008;588:99–105.
12.
Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron. 1988;1:85–96.
13.
Foumier AE, Grandpre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001;409:341–346.
14.
Jensen MB, Finsen B, Zimmer J. Morphological and immunophenotypic microglial changes in the denervated fascia dentata of adult rats: correlation with blood-brain barrier damage and astroglial reactions. Exp Neurol. 1997;143:103–116.
15.
Huang DW, McKerracher L, Braun PE, et al. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron. 1999;24:639–647.
16.
Kono DH, Urban JL, Horvath SJ, et al. Two minor determinant of myelin basic protein induce experimental allergic encephalomyelitis in SJL/J mice. J Exp Med. 1988;168:213–227.
17.
Yan H, Bunge MB, Wood PM, Plant GW. Mitogenic response of adult rat olfactory ensheathing glia to four growth factors. Glia. 2001;33:334–342.
DOI
18.
Gruner JA. A monitored contusion model of SCI in the rat. J Neurotrauma. 1992;9:123–128.
19.
Inman DM, Steward O. Ascending sensory, but not other long-tract axons, regenerate into the connective tissue matrix that forms at the site of a spinal cord injury in mice. J Comp Neurol. 2003;462:431–449.
20.
Raineteau O, Fouad K, Noth P, et al. Functional switch between motor tracts in the presence of the mAb IN-1 in the adult rat. Proc Natl Acad Sci U S A. 2001;98:6929–6934.
21.
Li S, Strittmatter SM. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci. 2003;23: 4219-4227.
22.
Ye JH, Houle JD. Treatment of the chronically injured spinal cord with neurotrophic factors can promote axonal regeneration from supraspinal neurons. Exp Neurol. 1997;143:70–81.
23.
Teng FY, Tang BL. Nogo signaling and non-physical injury-induced nervous system pathology. J Neurosci Res. 2005;79:273–278.
24.
Hauben E, Butovsky O, Nevo U, et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neuroscience. 2000;20:6421–6430.
Publication history
Copyright
Rights and permissions

Publication history

Published: 25 October 2013
Issue date: December 2013

Copyright

© 2013 The Author(s).

Rights and permissions

© 2013 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Return